Press Information Bureau: Digest for August 29, 2023

Business Wire India - Multimedia Multimedia By Business Wire India

Table of Contents Rela Hospital's Remarkable Breakthrough in Treating a Rare Complex Condition - NXP2 Dermatomyositis Treatment ZuAI Announces a INR 4 crore Fundraise Led by Prime Venture Partners Lizol's #NoMoreHalfTruths Campaign Busts Myths Around Phenyls; Receives Massive Traction on Social Media, Generating 800M+ Views

Rela Hospital's Remarkable Breakthrough in Treating a Rare Complex Condition - NXP2 Dermatomyositis Treatment Wednesday 05 July 2023 04:30 AM UTC+00 Business Wire India Rela Hospital is excited to announce a groundbreaking treatment in the battle against NXP2 Dermatomyositis, a rare and challenging autoimmune disease. A team of dedicated medical professionals and experts has achieved this unprecedented success bringing hope and relief to patients and their families worldwide. NXP2 Dermatomyositis is an exceptionally challenging disease that affects a small proportion of individuals worldwide. It is characterized by the presence of autoantibodies against the NXP2 protein, leading to severe inflammation of muscles and skin.   It all began when Dr. Gautam, a dedicated army professional, started experiencing stiffness in his joints accompanied by body aches. Initially attributing it to osteoarthritis, he sought the advice of a trusted colleague, an orthopedic surgeon, who recommended simple analgesics however despite a month of treatment, his symptoms persisted, leading him to seek further medical assistance. That's when Dr. Gautam approached Dr. (BRIG) Shanmuganandan, Rheumatologist at Rela Hospital. Recognizing the urgency of the situation, Dr. Shanmuganandan promptly ordered a series of tests to identify the underlying cause. Through meticulous examination and state-of-the-art investigative modalities available at Rela Hospital, the medical team identified a rare medical illness known as NXP2 Dermatomyositis. Early diagnosis was made possible by a thorough understanding of Dr. Gautam's medical history and diligent clinical care.   The key breakthrough lies in the development of targeted immunomodulatory treatments that address the underlying autoimmune mechanism responsible for NXP2 Dermatomyositis. The treatments aim to suppress the abnormal immune response, reduce inflammation, and restore normal muscle and skin function resulting in significant improvements in patients' overall well-being, including reduced muscle weakness, improved mobility, and enhanced skin health.   "Responding remarkably well to treatment, Dr. Gautam experienced a complete resolution of his earlier symptoms, bringing immense relief. However, his journey took an unexpected turn when he was diagnosed with tuberculosis in January. Once again, the exceptional clinical care, precise investigations, and cutting-edge treatment at Rela Hospital played a crucial role in identifying and treating this new challenge," said Dr. (BRIG) Shanmuganandan, Rheumatologist at Rela Hospital.   "Thanks to the dedicated efforts of Dr. Aishwarya, Dr. Sathya, Dr. (BRIG) Shanmuganandan, Dr. Vidyalakshmi​ Devarajan, and the entire healthcare team, I was diagnosed and treated with unparalleled expertise. Throughout my stay, spanning nearly ten days, I received comprehensive care from specialists, including vascular surgeons and hematologists. I am now leading a symptom-free life with complete remission of my illnesses," commented Dr. Gautam.

ZuAI Announces a INR 4 crore Fundraise Led by Prime Venture Partners Wednesday 05 July 2023 05:35 AM UTC+00 Business Wire India ZuAI, a Bangalore-based GenAI startup, today announced that it has raised INR 4 crore in seed funding led by Prime Venture Partners. The groundbreaking AI-powered personal tutor for students aims to enhance academic outcomes for one hundred million students in the next three years. This investment will propel the startup's (which was previously backed by 100X.VC) mission of providing personalized and effective learning experiences to students in India.   Founders Anubhav Mishra and Arpit Jain stumbled upon the idea of revolutionizing the education sector with Generative AI while building ZuPay and recently launched ZuAI for select pilot users. Since then it has received enthusiastic reviews and love from over 35,000 students. Over 4500 students are using it daily for their studies with students from grades 7 to 10 using it the most. The company plans to add more sophisticated tools which will allow learners to generate a study lecture within 5 minutes on any topic in the future. It will also offer adaptive test series that will enable learners to see progress in any topic they are learning.   ZuAI is aligned with the Indian CBSE, ICSE & State Board curriculum and is built on the NCERT recommended text books to provide a curriculum-based learning which is inline with the syllabus. ZuAI offers students a personalized and adaptive learning experience across various subjects. It is designed for students in grades 4-10 and helps them to learn from their prescribed textbooks, prepare for exams, revise concepts and generate notes on any topic. It boasts a range of cutting-edge features such as personalized learning paths, interactive lessons with multimedia resources, real-time feedback, comprehensive performance analytics, and 24x7 accessibility. ZuAI also supports multiple languages for a more inclusive learning experience for the student. It addresses individual learning styles and pace of every student to provide an always ready, infinitely patient, interactive tutor which is tailored to each learner's needs. It has the capability to generate any number of practice questions, providing learners ample opportunity to practice and solidify their understanding of any lesson or concept. By tailoring the learning experience to each student's unique needs, ZuAI aims to reshape the future of education.   According to Bloom's 2 sigma problem, 98% of students who receive one-to-one tutoring outperform peers who do not. It also notes that one-to-one tutoring is too expensive for most societies to bear on a large scale and here is where technologies like GenAI can prove to be transformational by providing affordable high quality educational tools to all. By providing access to personalized learning, ZuAI offers a new way of tutoring for hundreds of students who until now have had limited access to learning tools. A recent survey conducted by Intelligent, a prominent platform for higher-education planning, found that 85% students who have had the opportunity to utilize both ChatGPT and traditional tutoring sessions perceive ChatGPT as a more effective learning tool compared to traditional tutoring. Additionally, 96% of parents with school-age children also hold the belief that their children achieve better outcomes by studying with ChatGPT.   The funding round was led by Prime Venture Partners, a leading venture capital firm specializing in early-stage technology startups. The firm's deep expertise and commitment to supporting transformative technology initiatives for India made them an ideal partner for ZuAI.   Supporting Quotes   Anubhav Mishra, co-founder, ZuAI "We started ZuAI with a simple vision of enabling all students to have access to a personal tutor 24x7 and make learning interactive and personalized so that they can learn at their own pace. This investment will empower us to improve our platform's capabilities, reach more students in India, and make a lasting impact on their educational journey."   Sanjay Swamy, managing partner, Prime Venture Partners "GenAI is driving a massive transformation in education and ZuAI's key insight is that curriculum-based education is where the action is, and where a personalized tutor can truly change outcomes for students. We're delighted to back the ZuAI team to help students benefit from the state-of-the-art in AI, while also giving parents the comfort that their children will get coaching that is both relevant and curriculum specific, without the broader distractions of the Internet."   Ninad Karpe, founder & partner, 100X.VC As the first investor in Zu Technologies, we are delighted that they have raised the next round of funding. We believe that ZuAi is on a path to bring about a paradigm shift in the education sector in India and we are excited about the potential it holds for rapid growth."

Lizol's #NoMoreHalfTruths Campaign Busts Myths Around Phenyls; Receives Massive Traction on Social Media, Generating 800M+ Views Wednesday 05 July 2023 09:15 AM UTC+00 Business Wire India For decades, Indian consumers have believed that phenyls are highly effective floor cleaners, however studies indicate that ordinary phenyls kill only 50% of germs on mopping**. A joint study conducted by Lizol, India's leading disinfectant brand, and an independent research agency revealed the presence of numerous bacteria and viruses on household surfaces, which can lead to various diseases and infections. These can be responsible for diseases, such as diarrhoea, and conditions like skin infections, urinary tract infections, acne, eye and bloodstream infections. In response, Lizol launched the #NoMoreHalfTruths social media campaign on May 29, 2023, aimed at debunking the myths surrounding phenyl efficacy and increasing consumer awareness about proper cleaning practices.   The campaign aimed to raise awareness about the limited effectiveness of the commonly used household cleaner, phenyl, in killing germs. It highlighted that ordinary phenyls only eliminate 50% of germs** when used for mopping. Additionally, Lizol received recognition for its product's superior formulation, offering 99.9% germ kill** with just one cap, along with 10 times better cleaning* compared to three caps of phenyl. #NoMoreHalfTruths gained significant traction on social media, accumulating over 800 million views and generating more than 50 million likes, comments, and shares across various platforms.   Mr. Saurabh Jain, Regional Marketing Director, Hygiene, Reckitt- South Asia said, "A recent study revealed that illness-causing germs found in hospitals are also widespread on the floors of Indian households, posing a health risk to families. The #NoMoreHalfTruths campaign aims to educate consumers about these germs in their homes and the inadequacy of ordinary phenyls in eliminating them. The success of this campaign underlines the potential power of digital Indian audiences and our ability to initiate a movement by engaging them. We also want to ensure school kids are protected from the risk of falling ill due to unclean surfaces, thus we have partnered with The Akshaya Patra Foundation, which marks the beginning of a commitment to ensuring overall surface protection with Lizol."   As part of the campaign, Lizol collaborated with prominent celebrities like Sameera Reddy, Neha Dhupia, and Gurmeet Choudhary to actively engage and inform consumers about the limited effectiveness of phenyls in cleaning surfaces. The campaign aimed to encourage people to join the movement and expose the misconception that phenyls are highly effective in killing germs, when in reality they only eliminate 50% of germs**. In line with its commitment to protecting families and promoting a germ-free environment, Lizol also partnered with The Akshaya Patra Foundation to provide cleaning products for kitchen and school floors.   Mr. Anant Arora, Chief Communication & Sustainability Officer, The Akshaya Patra Foundation said, "The Akshaya Patra Foundation strives to empower children with a healthy and wholesome meal to ensure nourishment & better learning experience. Ensuring children's health and safety is paramount, and we are proud of our partnership with Lizol, an expert in maintaining global standards of cleanliness and hygiene. Together, we are creating a brighter, healthier tomorrow for the children we serve." Sameera Reddy's post: https://www.instagram.com/reel/CtDvyDVAApO/?igshid=NTc4MTIwNjQ2YQ== https://www.instagram.com/reel/CtdneAoAmqo/?igshid=NTc4MTIwNjQ2YQ==   Neha Dhupia's post: https://www.instagram.com/reel/Cs_LU7MgkhR/?igshid=NTc4MTIwNjQ2YQ== https://www.instagram.com/reel/Ctda4XXA5eS/?igshid=NTc4MTIwNjQ2YQ==   Gurmeet Choudhry's post: https://www.instagram.com/reel/Cs-rHFopnO6/?igshid=NTc4MTIwNjQ2YQ==   * As per lab testing vs ordinary white phenyls **As per lab testing done on representative bacteria on recommended dilution for ordinary white phenyls and Lizol

You received this email because you set up a subscription at Feedrabbit. This email was sent to you at epaperindia10@gmail.com. Unsubscribe or change your subscription.